Next Article in Journal
Delivery of RNAi-Based Oligonucleotides by Electropermeabilization
Next Article in Special Issue
Targeting Platelet Thrombin Receptor Signaling to Prevent Thrombosis
Previous Article in Journal
NMDA Receptor Antagonists for Treatment of Depression
Previous Article in Special Issue
Pathophysiology of GPCR Homo- and Heterodimerization: Special Emphasis on Somatostatin Receptors
Article Menu

Export Article

Open AccessArticle
Pharmaceuticals 2013, 6(4), 500-509;

The Three Catecholics Benserazide, Catechol and Pyrogallol are GPR35 Agonists

Biochemical Technologies, Science and Technology Division, Corning Inc., Corning, NY 14831, USA
Author to whom correspondence should be addressed.
Received: 6 March 2013 / Revised: 20 March 2013 / Accepted: 1 April 2013 / Published: 8 April 2013
(This article belongs to the Special Issue GPCR Based Drug Discovery)
Full-Text   |   PDF [939 KB, uploaded 8 April 2013]   |  


Nearly 1% of all clinically used drugs are catecholics, a family of catechol-containing compounds. Using label-free dynamic mass redistribution and Tango β-arrestin translocation assays, we show that several catecholics, including benserazide, catechol, 3-methoxycatechol, pyrogallol, (+)-taxifolin and fenoldopam, display agonistic activity against GPR35. View Full-Text
Keywords: GPR35; benserazide; catechol; pyrogallol GPR35; benserazide; catechol; pyrogallol

Figure 1

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Deng, H.; Fang, Y. The Three Catecholics Benserazide, Catechol and Pyrogallol are GPR35 Agonists. Pharmaceuticals 2013, 6, 500-509.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top